Association of simple renal cysts with metabolic syndrome in adults

Wei-Chen Shen¹, Zih-Jie Sun¹,², Chieh-Ying Chou¹, Yu-Tsung Chou¹,³, Feng-Hwa Lu¹,⁴, Yi-Ching Yang¹,⁴, Chih-Jen Chang¹,⁵ and Jin-Shang Wu¹,²,³,⁴*

¹Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ²Division of Family Medicine, National Cheng Kung University Hospital Dou-Liou Branch, College of Medicine, National Cheng Kung University, Yulin, Taiwan, ³Department of Health Management Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ⁴Department of Family Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ⁵Department of Family Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan

Background and aims: Metabolic syndrome is common nowadays and may increase risk of hypertension, type 2 diabetes mellitus, cardiovascular complications and even mortality. Renal cysts are also frequently found during routine examination. However, the relationship between simple renal cysts (SRCs) and metabolic syndrome remains unclear. This study aimed to investigate the association of SRCs with metabolic syndrome.

Methods: A total of 16,216 subjects aged ≥18 years were enrolled in this study. SRCs were diagnosed with ultrasonography by finding: sharp, thin posterior walls, a round/oval shape, absence of internal echoes, and posterior enhancement. SRCs were categorized by number (0, 1, and ≥2) and size (<2 and ≥2 cm). Metabolic syndrome was diagnosed according to the consensus statement from the International Diabetes Federation.

Results: In multivariate analysis, SRCs were positively related to metabolic syndrome (OR: 1.18, 95% CI: 1.06–1.34). The risk of metabolic syndrome was higher for SRCs with a number ≥2 (OR: 1.35, 95% CI: 1.08–1.68) and size ≥2 cm (OR: 1.33, 95% CI: 1.10–1.61). When considering the SRC number and size concomitantly, SRCs with a number ≥2/size ≥2 cm (OR: 1.42, 95% CI: 1.02–1.98) or <2/size ≥2 cm (OR: 1.30, 95% CI: 1.04–1.62) were positively related to metabolic syndrome.

Conclusions: Simple renal cysts were found to be related to a higher risk of metabolic syndrome, and the association is more significant in those with larger (sizes ≥2 cm) or plural (numbers ≥2) SRCs.

KEYWORDS
renal cyst, metabolic syndrome, insulin resistance, hypertension, metabolic disease
Introduction

Renal cystic diseases are classified into inherited, developmental and acquired condition according to their etiologies (1, 2). Simple renal cysts (SRCs) are a common type of acquired cysts, or part of acquired cystic kidney diseases (3), and are often found incidentally. The prevalence of SRCs varies from 5.0 to 20.8% in different countries (4, 5). One cross-sectional study demonstrated that the prevalence was 10.7% among Taiwanese people (6), and it is believed that the incidence of SRCs increases with age (4, 7–9). SRCs are thought to be benign, asymptomatic lesions in clinical practice, rarely requiring invasive intervention (3). However, studies have revealed that SRCs were associated with hypertension, elevated serum creatinine, and hyperuricemia (4, 8–11). Thus, more studies are needed to elucidate whether SRCs are potentially related to other negative health impacts.

Although the definition of metabolic syndrome differs among organizations, the key components include insulin resistance, glucose intolerance, central obesity, hypertension, and dyslipidemia (12). The diagnostic criteria of metabolic syndrome are easily accessed and were applied rapidly in clinical practice (12–14). The importance of metabolic syndrome has been raised nowadays since the presence of metabolic syndrome increases the risk of hypertension, type 2 diabetes mellitus (DM), non-alcoholic fatty liver diseases (15), cardiovascular complications and mortality (16).

Previous studies have targeted the association of SRCs with individual cardio-metabolic related disorders, such as obesity (11) hypertension (10), prehypertension (10), renal dysfunction (7, 17), and hyperuricemia (18). However, study that focus on the relationship between metabolic syndrome and SRCs is lacking. Furthermore, whether the characteristics of SRCs, such as the size or number of SRCs have impacts on metabolic syndrome remains indeterminate. Considering that metabolic syndrome significantly raises the risk of DM, heart disease, and mortality, investigating the possible impact of SRCs on metabolic syndrome may provide one additional route for further researches and clinical practice of metabolic abnormalities. Thus, the aim of the present study was to clarify the association of SRCs with metabolic syndrome.

Methods

Study population

Subjects who underwent a health examination were recruited at the National Cheng Kung University Hospital from June 2001 to August 2009. A total of 16,216 subjects were enrolled for final analysis after excluding subjects aged <18 years, taking medication for obesity management, history of bariatric surgery, pregnant women, or history of or abdominal sonography with the following findings: renal stone, renal cyst with calcification, any cause of hydronephrosis, medullary sponge kidney disease, medullary cystic kidney disease, renal ectopia, polycystic kidney disease, renal tumor, renal transplantation and status post-nephrectomy, and incomplete data. This study was approved by the Institutional Review Board of National Cheng Kung University Hospital in Taiwan (IRB number: B-ER106-066).

A standardized self-reported questionnaire was completed by every participant and was used to obtain demographic information, medical history, and lifestyle habits, including smoking, alcohol drinking, and regular exercise. Current alcohol drinkers were defined as those who had at least one alcoholic drink per week for at least the previous 6 months (19). Current smoking status was defined as at least 20 cigarettes per month during the past 6 months. Regular exercise was defined as exercise at least three times per week for a minimum of 20 min (19).

Body height and weight were measured by a certified anthropometry instrument (to the nearest 0.1 cm and 0.1 kg, respectively). Body mass index (BMI) was calculated as weight (kilograms) divided by height (m) squared (kg/m$^2$). Subjects with a BMI ≥27 kg/m$^2$ were defined as obese according to the guidelines of the Department of Health in Taiwan (20). Waist circumference (WC) was measured from the midway between the lower rib margin and the iliac crest with a standing posture (to the nearest 0.1 cm) at the end of a normal expiration. After 5 min of rest, the right branchial artery blood pressure was measured in the supine position by using a DINAMAP vital sign monitor (model 1846SX; Critikon, Irvine, CA) with an appropriate-sized cuff. Two blood pressure readings were taken separately under an interval of at least 5 min. Hypertension was diagnosed by a positive history of hypertension and the reading from the right branchial artery showing a systolic blood pressure (SBP) of 140 mmHg or more, or diastolic blood pressure (DBP) 90 mmHg or more (21).

After overnight fasting for 12 h, all participants received blood sampling for biochemical examinations, which included the following: fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), uric acid and creatinine. Serum TC, TG and HDL-C levels were determined in the central laboratory of NCKUH with an autoanalyzer (Hitachi 747E, Tokyo, Japan). Patients’ 2-h post-load glucose (2-h PG) was checked after a 75-g oral glucose tolerance test for all participants without DM or pregnancy. DM was defined as a positive history, FPG ≥126 mg/dl, 2-h PG ≥200 mg/dl or HbA1c ≥6.5% (21). All participants were divided into two groups by the presence of metabolic syndrome or not, which was defined according to the consensus statement from the International Diabetes Federation (22). Metabolic syndrome was diagnosed if a participant had central obesity (WC ≥90 cm in men or...
shows the clinical characteristic between participants
Public Health
demonstrates the multiple logistic regression model
26
frontiersin.org/zero.tnum/three.tnum
further demonstrated that subjects with SRCs have
internal echoes, and (4) posterior enhancement (thin posterior walls, (2) round/oval shape, (3) absence of
the criteria of abdominal sonography, including: (1) sharp,
3.5-MHz transducer). The diagnosis of SRCs was based on
numbers (≥2 and ≥2 cm) and
Statistical analyses
Statistical analyses were performed by using Windows SPSS
17.0 statistical software (Chicago, Illinois, USA). In univariate
analysis, the comparison of continuous variables was carried out
Student's t-tests and categorical variables by Pearson Chi
square tests between two groups. A binary logistic regression
model was performed to investigate whether the SRCs were
associated with an increased risk of metabolic syndrome. Other
independent factors included age, gender, obesity, creatinine,
uric acid, alcohol drinking, smoking, and regular exercise.
Furthermore, the associations of the size, number, and the
combined characteristics of SRCs with metabolic syndrome
were also examined. The p-value <0.05 was considered as
statistically significant.
Results
A total of 16,216 subjects were enrolled and divided into
two groups according to the presence of metabolic syndrome.
Table 1 shows the clinical characteristic between participants
with (n = 4,071) and without metabolic syndrome (n = 12,145). Subjects with metabolic syndrome were predominantly
older males and tended to have higher BMI, SBP, DBP, FPG,
cholesterol, TG, uric acid, and creatinine, as well as the
prevalence of obesity, hypertension, DM, and current tobacco
and alcohol consumption, together with a lower HDL-C and
prevalence of regular exercise.
Table 2 further demonstrated that subjects with SRCs have
higher prevalence of metabolic syndrome. It also showed that
those with larger (size ≥2 cm) or plural (number ≥2) SRCs were
more likely to have metabolic syndrome.
Table 3 demonstrates the multiple logistic regression model
for the relationship between SRCs and metabolic syndrome
with adjustment for other covariates, including age, gender,
obesity, creatinine, uric acid, alcohol consumption, smoking,
and regular exercise. SRCs were associated with an increased risk
of metabolic syndrome (model 1, OR: 1.18, 95% CI: 1.06–1.34,
p = 0.007). We further explored the relationship between the
number and size of SRCs and metabolic syndrome (models 2–
4), and found that the associated risk of metabolic syndrome was
significantly higher in those with an SRC number ≥2 (model 2,
OR: 1.35, 95% CI: 1.08–1.68, p = 0.008) and size ≥2 cm (model
3, OR: 1.33, 95% CI: 1.10–1.61, p = 0.003). Model 4 revealed that
when the number and size of the SRCs were considered
concomitantly, those with an SRC size ≥2 cm had higher
associated risk of metabolic syndrome, regardless of whether
the number of SRCs was single (OR:1.30, 95% CI: 1.04–1.62,
p = 0.021) or multiple (OR: 1.42, 95% CI: 1.02–1.98, p = 0.040).
In subjects with an SRC number ≥2 and < 2 cm, the associated
risk for metabolic syndrome was statistically borderline (OR:
1.30, 95% CI: 0.98–1.73, p = 0.065). Singular SRCs of <2 cm
were not associated with higher risk of metabolic syndrome (OR:
1.04, 95% CI: 0.88–1.24, p = 0.645). However, both number
≥2/size ≥2 cm (OR: 1.42, 95% CI: 1.02–1.98, p = 0.04) and
number <2/size ≥2 cm (OR: 1.30, 95% CI: 1.04–1.62, p = 0.021)
were positively related to metabolic syndrome. In addition,
metabolic syndrome was also positively associated with older
age, obesity, uric acid level and smoking, but inversely related to
regular exercise.
Discussion
Principal findings
Our study found that presence of SRCs is positively
associated with risk of metabolic syndrome, especially in those
with larger or plural SRCs. To the best of our knowledge, this
is the first study to investigate the association of SRCs and its
characteristics with metabolic syndrome with adjustments
for many important cardio-metabolic variables in a relatively
large population. Although the mechanism underlying the link
between SRCs and metabolic syndrome is still unclear, recent
studies showed that SRCs were found to be associated with an
increased risk of albuminuria in young adults (24) and SRCs
are also associated with worse renal function in type 2 diabetes
patients (25). The negative impact of SRCs in general population
of this study was similar to young adults and diabetes patients in
the two studies mentioned above (24, 25).
SRCS and metabolic disorders
According to previous studies about the association between
SRCS and cardio-metabolic factors, it has been confirmed that
SRCS are associated with elevated blood pressure (10, 26). Lee
et al. found that SRCS were related to prehypertension and
TABLE 1 Comparisons of clinical characteristics between subjects with and without metabolic syndrome.

| Variables                        | Metabolic syndrome | p-Value |
|----------------------------------|--------------------|---------|
|                                  | No (n = 12,145)    | Yes (n = 4,071) |
| Age, years                       | 47.6 ± 12.6        | 54.3 ± 12.0        | <0.001 |
| Male                             | 6,959 (57.3)       | 2,751 (67.6)       | <0.001 |
| BMI, kg/m²                       | 23.5 ± 3.2         | 27.1 ± 3.3         | <0.001 |
| BMI ≥ 27 kg/m²                   | 1,440 (42.6)       | 1,941 (47.7)       | <0.001 |
| Waist circumference, cm          | 81.0 ± 12.0        | 115.6 ± 1,457.9    | 0.009  |
| Central obesity                  | 2,866 (23.6)       | 3,453 (84.8)       | <0.001 |
| SBP, mmHg                        | 114.8 ± 15.8       | 131.4 ± 18.6       | <0.001 |
| DBP, mmHg                        | 67.9 ± 10.1        | 76.9 ± 11.1        | <0.001 |
| Elevated BP*                     | 1,867 (15.4)       | 2,319 (57)         | <0.001 |
| Hypertension                     | 1,357 (11.2)       | 1,843 (45.3)       | <0.001 |
| FPG, mg/dl                       | 89.3 ± 17.0        | 111.2 ± 40.1       | <0.001 |
| Hemoglobin A1c, %                | 5.6 ± 0.7          | 6.4 ± 1.5          | <0.001 |
| Hyperglycemia (FPG > 100 mg/dl)  | 1,103 (9.1)        | 2,274 (55.9)       | <0.001 |
| Diabetes mellitus                | 1,128 (9.3)        | 1,662 (40.8)       | <0.001 |
| Cholesterol, mg/dl               | 194.5 ± 36.7       | 204.0 ± 39.2       | <0.001 |
| Triglyceride, mg/dl              | 108.5 ± 61.8       | 207.5 ± 133.1      | <0.001 |
| Hypertriglyceridemia (TG > 150 mg/dl) | 1,746 (14.4) | 2,886 (70.9) | <0.001 |
| HDL-C, mg/dl                     | 52.0 ± 13.5        | 39.1 ± 9.3         | <0.001 |
| Low HDL-C**                      | 3,023 (24.9)       | 3,092 (76)         | <0.001 |
| Creatinine, mg/dl                | 0.87 ± 0.40        | 0.93 ± 0.44        | <0.001 |
| eGFR, ml/min/1.73m²              | 95.2 ± 16.0        | 88.3 ± 16.9        | <0.001 |
| Uric acid, mg/dl                 | 5.9 ± 1.5          | 6.7 ± 1.6          | <0.001 |
| ALT, U/L                         | 29.7 ± 32.8        | 43.6 ± 40.3        | <0.001 |
| Current alcohol consumption      | 1,344 (11.1)       | 525 (12.9)         | 0.002  |
| Current smoking                  | 1,234 (10.2)       | 556 (13.7)         | <0.001 |
| Regular exercise ≥ 3/week         | 1,010 (8.3)        | 279 (6.9)          | 0.003  |

Data expressed as means ± standard deviation or number (percent). BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; ALT, alanine aminotransferase; HDL-C, high-density lipoprotein-cholesterol; eGFR, estimated glomerular filtration rate.

*Elevated BP: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg.
**Low HDL: HDL < 40 mg/dl in males and < 50 in females.

hypertension and larger (size ≥ 2 cm) and multiple renal cysts (number ≥ 2), which further elevated the associated risk of prehypertension and hypertension (10). Hong et al. (26) also demonstrated a positive relationship between hypertension and SRCs, especially in those with larger (size ≥ 1.4 cm) or multiple (number ≥ 2) SRCs (26). Nevertheless, the association between SRCs and DM remains inconsistent (4, 7–9, 11), and adjustments for important covariates, such as age (7), sex (7), blood pressure (7–9), and lifestyle habits (e.g. smoking (7–9, 11), alcohol consumption (4, 7–9, 11) and exercise (4, 7–9, 11) are lacking in previous studies. Although high BMI was positively associated with SRCs in a healthy Korean population (11), the association of SRCs with central obesity and dyslipidemia has not been studied. Our study showed that subjects with SRCs may have a higher associated risk of metabolic syndrome after adjusting for other variables. The associated risk of metabolic syndrome were higher in subjects with SRCs, especially for sizes ≥ 2 cm or numbers ≥ 2.

Mechanism of SRCs and metabolic syndrome

The exact mechanism for the relationship between SRCs and metabolic syndrome remains unclear. However, SRCs were found to have impacts on (1) renin-angiotensin-aldosterone system (RAAS), (2) insulin resistance, and (3) chronic inflammation, which are all essential in the pathogenesis of metabolic syndrome (27, 28). The serum renin level was higher in subjects with multiple (number ≥ 2) and larger
TABLE 2  Relationship between metabolic syndrome and renal cyst by Pearson Chi-square test.

| Variables                  | Metabolic syndrome | p-Value |
|----------------------------|--------------------|---------|
|                            | No (n = 12,145)    | Yes (n = 4,071) |         |
| Presence of renal cyst     |                    |         |
| No                         | 11,026 (90.8)      | 3,487 (85.7) | <0.001 |
| Yes                        | 1,119 (9.2)        | 584 (14.3)  |         |
| Renal cyst, number         |                    |         |
| <2                         | 854 (7.0)          | 409 (10.0)  | <0.001 |
| ≥2                         | 265 (2.2)          | 32 (4.3)    |         |
| Renal cyst, size           |                    |         |
| <2 cm                      | 747 (6.2)          | 347 (8.5)   | <0.001 |
| ≥2 cm                      | 372 (3.1)          | 237 (5.8)   |         |
| Renal cyst, number and size|                    |         |
| Number <2 and size <2 cm  | 588 (4.8)          | 246 (6.0)   | <0.001 |
| Number ≥2 and size <2 cm  | 159 (1.3)          | 101 (2.5)   |         |
| Number <2 and size ≥2 cm  | 266 (2.2)          | 163 (4.0)   |         |
| Number ≥2 and size ≥2 cm  | 106 (0.9)          | 74 (1.8)    |         |

Data expressed as means ± standard deviation or number (percent).
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; ALT, alanine aminotransferase; HDL-C, high-density lipoprotein-cholesterol; eGFR, estimated glomerular filtration rate.

(size ≥2 cm) SRCs (10), which may increase RAAS activity and contribute to the development of elevated blood pressure (29, 30). In addition, renalse, derived from the kidney, of which levels were lower in subjects with renal cysts (31), may play a role through its degradation of serum catecholamines in the blood (32). Lower renalse levels in subjects with SRCs (31) may possibly result in excess catecholamine, and thus partially contributes to increased insulin resistance. We also additionally analyzed the relationship between SRCs and MS with concomitant consideration of individual MS component (Supplementary Table 2). The statistical significance of the positive relationship between SRCs and MS were attenuated to be insignificant when elevated blood pressure or hyperglycemia was adjusted, but the association between SRCs and MS remained significant when hypertriglyceridemia, low HDL-C or central obesity was adjusted in separate models. The results provided that the association of SRCs and MS might be mediated by abnormal blood pressure and hyperglycemia. As for SRCs and chronic inflammation, subjects with SRCs had more activated RAAS, which may induce increased systemic inflammation (33, 34). Furthermore, excess of catecholamine caused by lower renalse levels in subjects with SRCs, also potentially increased systemic inflammation (35–37). Therefore, elevated activity of RAAS, increased insulin resistance and chronic systemic inflammation may help to explain the pathogenesis of metabolic syndrome in subjects with SRCs.

In this study, metabolic syndrome was also shown to be positively related to older age, obesity, uric acid level and cigarette smoking; in contrast, regular exercise was inversely related to the risk of metabolic syndrome. These results are compatible with previous studies (15, 38–40). Aging was commonly associated with increased body fat, decreased muscle mass (22) and increased oxidative stress (41), which were all crucial for developing insulin resistance and subsequent metabolic syndrome (22, 27, 42). In addition, age was also found to be associated with formation and growth of SRCs (43). Previous study also showed an increase in the frequency of cysts with advanced age and growth in volume with a doubling of their volume after about 10 years (6). Besides, our analysis also showed that age was the major factor that associated with SRCs (shown in Supplementary Table 1). As a result, age may potentially modulate the interaction between SRCs and MS. Obesity was associated with visceral fat deposit, elevated free fatty acid levels, and increased systemic inflammatory cytokines (27, 44), which may inevitably result in the evolution of metabolic syndrome. As for uric acid level and metabolic syndrome, previous studies have demonstrated that uric acid not only induced hepatic gluconeogenesis, hepatic fat accumulation and oxidative stress, but also exacerbated the development of insulin resistance, hypertension and metabolic syndrome (45, 46). Smoking was also found to be associated with metabolic syndrome through its effect on elevating blood pressure, increasing insulin resistance and altering lipid metabolism (40). A previous study found that exercise helped correct metabolic imbalance by reducing blood pressure, blood sugar and triglyceride levels, and waist circumference, as well as by increasing the serum HDL-C level (40), which may partially
TABLE 3 Logistic regression models for the association of simple renal cysts with metabolic syndrome.

|                                | Model 1                      | Model 2                      | Model 3                      | Model 4                      |
|--------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                | OR (95% CI)                  | OR (95% CI)                  | OR (95% CI)                  | OR (95% CI)                  |
| Age, 40–65 vs. <40 years       | 2.84 (2.53–3.19)***          | 2.84 (2.53–3.19)***          | 2.84 (2.53–3.19)***          | 2.84 (2.53–3.19)***          |
| Age, >65 vs. <40 years         | 5.88 (5.06–6.84)***          | 5.84 (5.02–6.80)***          | 5.85 (5.03–6.81)***          | 5.82 (5.00–6.77)***          |
| Male vs. female                | 0.94 (0.85–1.04)             | 0.94 (0.85–1.03)             | 0.94 (0.85–1.04)             | 0.94 (0.85–1.03)             |
| Obesity, yes vs. no            | 5.92 (5.42–6.45)***          | 5.92 (5.42–6.46)***          | 5.91 (5.42–6.45)***          | 5.92 (5.42–6.46)***          |
| Creatinine, mg/dl              | 0.91 (0.82–1.02)             | 0.91 (0.81–1.02)             | 0.91 (0.82–1.02)             | 0.91 (0.81–1.02)             |
| Uric acid, mg/dl               | 1.31 (1.27–1.35)***          | 1.31 (1.27–1.35)***          | 1.31 (1.27–1.35)***          | 1.31 (1.27–1.35)***          |
| Current alcohol consumption, yes vs. no | 0.92 (0.81–1.04)             | 0.92 (0.80–1.04)             | 0.92 (0.81–1.04)             | 0.92 (0.80–1.04)             |
| Current smoking, yes vs. no    | 1.50 (1.32–1.71)***          | 1.51 (1.32–1.71)***          | 1.50 (1.32–1.71)***          | 1.50 (1.32–1.71)***          |
| Regular exercise ≥3/week, yes vs. no | 0.75 (0.64–0.87)***          | 0.75 (0.65–0.88)***          | 0.75 (0.64–0.88)***          | 0.75 (0.65–0.88)***          |
| Simple renal cysts, yes vs. no | 1.18 (1.05–1.34)**           | 1.13 (0.98–1.30)             | 1.10 (0.95–1.28)             | 1.35 (1.08–1.68)**           |

Number of simple renal cysts

| <2 vs. none | 1.13 (0.98–1.30) |
| ≥2 vs. none | 1.35 (1.08–1.68)** |

Size of simple renal cysts

| <2 cm vs. none | 1.10 (0.95–1.28) |
| ≥2 cm vs. none | 1.33 (1.10–1.61)** |

Combination of number and size

| Number <2 and size <2 cm vs. none | 1.04 (0.88–1.24) |
| Number ≥2 and size <2 cm vs. none | 1.30 (0.98–1.73) |
| Number <2 and size ≥2 cm vs. none | 1.30 (1.04–1.62)* |
| Number ≥2 and size ≥2 cm vs. none | 1.42 (1.02–1.98)* |

*p < 0.05.

**p < 0.01.

***p < 0.001.

OR, odds ratio; CI, confidence interval.

Bold values denote statistical significance at the p < 0.05 level.

explain the inverse relationship between regular exercise and metabolic syndrome.

Limitation

This study has the strength of a relatively large sample, comprehensive serologic data and concomitant adjustment of important covariates of metabolic syndrome. However, there are also several limitations to this study. First, because this study had a cross-sectional design, it is impossible to establish a causal relationship between metabolic syndrome and renal cysts. Second, we did not obtain the detailed dietary histories of the participants in this study. Third, the information of some diseases such as maturity onset diabetes of the young type 5 (MODY 5) or hyperaldosteronism, which may correlate renal cyst with metabolic syndrome (47–50), is lacking. Although the prevalence of MODY 5 and hyperaldosteronism is relatively low, further study with comprehensive information of such diseases is still helpful to clarify their impacts on relationship between SRCs and metabolic syndrome. Fourth, thorough evaluation of metabolic syndrome includes more specific laboratory information including high sensitivity C-reactive protein, inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-6, homeostatic model assessment for insulin resistance, microalbuminuria as well as endothelial function measurements (51–54), which were not examined in this study. Apart from this, the serum renelase, an enzyme that may potentially explain the interaction between renal cysts and metabolic syndrome, was not available. Therefore, future investigation that takes account of both renelase and thorough evaluation of metabolic syndrome may be necessary to disclose the possible mechanism about the relationship between SRCs and metabolic syndrome.

In conclusion, SRCs were related to a higher associated risk of metabolic syndrome, and the association is more significant in those with larger (sizes ≥2 cm) or plural (numbers ≥2) SRCs. Our data suggest that presence of SRCs, even with incidental finding, might require a further survey of potential metabolic syndrome. Although there have been some predictive models of metabolic syndrome (55–57), clinical application of SRCs in the risk stratification needs further investigation.
Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the Institutional Review Board of National Cheng Kung University Hospital, Tainan, Taiwan. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

Conceptualization: W-CS. Methodology: W-CS, Z-JS, and C-YC. Formal analysis and investigation: Z-JS and C-YC. Writing—original draft preparation: W-CS and Y-TC. Writing—review and editing: W-CS, Y-TC, and J-SW. Resources: Y-TC, F-HL, Y-CY, C-JC, and J-SW. Supervision: J-SW. All authors contributed to the article and approved the submitted version.

Funding

This research was funded by the National Cheng Kung University Hospital, Taiwan (Grant Number: NCKUH-11103034).

Acknowledgments

We are grateful to the investigators and staff of the Department of Family Medicine and Health Management Center of National Cheng Kung University Hospital for excellent research assistance. We are also grateful to Paul Spence (Foreign Language Center, College of Liberal Arts, National Cheng Kung University) for the assistance of editing this manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.951638/full#supplementary-material

References

1. Katabathina VS, Kota G, Dasgupta AK, Shanbhogue AK, Prasad SR. Adult renal cystic disease: a genetic, biological, and developmental primer. Radiographics. (2010) 30:1509–23. doi: 10.1148/rg.306105513
2. Bonsib SM. The classification of renal cystic diseases and other congenital malformations of the kidney and urinary tract. Arch Pathol Lab Med. (2010) 134:554–68. doi: 10.3858/134.5.554
3. Simms RJ, Ong AC. How simple are ‘simple renal cysts’? Nephrol Dial Transplant. (2014) 29:n106–12. doi: 10.1093/ndt/gfu106
4. Terada N, Araya Y, Kinukawa N, Yoshimura K, Terai A. Risk factors for renal cysts. BJU Int. (2004) 93:1300–2. doi: 10.1111/j.1464-410X.2004.04844.x
5. Pedersen JR, Emamian SA, Nielsen MB. Simple renal cyst: relations to age and arterial blood pressure. Br J Radiol. (1993) 66:581–4. doi: 10.1259/0007-1289-66-787-581
6. Chang CC, Kuo JY, Chan WL, Chen KK, Chang LS. Prevalence and clinical characteristics of simple renal cyst. J Chin Med Assoc. (2007) 70:486–91. doi: 10.1016/S1726-4901(07)00467-7
7. Chen J, Ma X, Xu D, Cao W, Kong X. Association between simple renal cyst and kidney damage in a Chinese cohort study. Ren Fail. (2019) 41:600–6. doi: 10.1080/0886022X.2019.1632718
8. Han Y, Zhang M, Lu J, Zhang I, Han J, Zhao F, et al. Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes. Sci Rep. (2017) 7:3802. doi: 10.1038/s41598-017-04036-6
9. Ozveren B, Onganer E, Turkeri LN. Simple renal cysts: prevalence, associated risk factors and follow-up in a health screening cohort. Urol J. (2016) 13:2569–75.
10. Lee CT, Yang YC, Wu JS, Chang YF, Huang YH, Lu FH, et al. Multiple and large simple renal cysts are associated with prehypertension and hypertension. Kidney Int. (2013) 83:924–30. doi: 10.1038/ki.2012.481
11. Choi JD. Clinical characteristics and long-term observation of simple renal cysts in a healthy Korean population. Int Urol Nephrol. (2016) 48:319–24. doi: 10.1007/s11255-015-1186-7
12. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. (2005) 365:1415–28. doi: 10.1016/S0140-6736(05)66378-7
13. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SE, Shaw LJ, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Circulation. (2004) 109:706–13. doi: 10.1161/01.CIR.0000115514.44135.A8
